ATE130293T1 - Tamoxifenderivate mit hoher affinität und ihre verwendung. - Google Patents

Tamoxifenderivate mit hoher affinität und ihre verwendung.

Info

Publication number
ATE130293T1
ATE130293T1 AT91919917T AT91919917T ATE130293T1 AT E130293 T1 ATE130293 T1 AT E130293T1 AT 91919917 T AT91919917 T AT 91919917T AT 91919917 T AT91919917 T AT 91919917T AT E130293 T1 ATE130293 T1 AT E130293T1
Authority
AT
Austria
Prior art keywords
tamoxifen
derivatives
tamoxifen derivatives
estrogen
substituted
Prior art date
Application number
AT91919917T
Other languages
English (en)
Inventor
David Yang
Sidney Wallace
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/589,928 external-priority patent/US5219548A/en
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE130293T1 publication Critical patent/ATE130293T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
AT91919917T 1990-10-01 1991-09-27 Tamoxifenderivate mit hoher affinität und ihre verwendung. ATE130293T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/589,928 US5219548A (en) 1990-10-01 1990-10-01 High affinity halogenated-tamoxifen derivatives and uses thereof
US07/722,322 US5192525A (en) 1990-10-01 1991-06-28 High affinity tamoxifen derivatives and uses thereof

Publications (1)

Publication Number Publication Date
ATE130293T1 true ATE130293T1 (de) 1995-12-15

Family

ID=27080697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919917T ATE130293T1 (de) 1990-10-01 1991-09-27 Tamoxifenderivate mit hoher affinität und ihre verwendung.

Country Status (7)

Country Link
EP (1) EP0551434B1 (de)
JP (1) JPH06504522A (de)
AT (1) ATE130293T1 (de)
AU (1) AU664161B2 (de)
CA (1) CA2092996A1 (de)
DE (1) DE69114719T2 (de)
WO (1) WO1992006068A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6083990A (en) 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
EE200000077A (et) 1997-08-15 2000-12-15 Duke University Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
JP2006528648A (ja) * 2003-07-24 2006-12-21 ザ クイーンズ メディカル センター アルキル化剤の調製及び使用
KR101505884B1 (ko) 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
CN101636372B (zh) 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
EA029881B1 (ru) * 2013-04-24 2018-05-31 Смарт Брейн С.Р.О. Производные тамоксифена для лечения новообразований, особенно с высоким уровнем белка her2
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
EP3459936B1 (de) * 2016-06-27 2022-04-27 Daegu-Gyeongbuk Medical Innovation Foundation Neuartiges arylethanderivat und pharmazeutische zusammensetzung damit als wirkstoff
JP2021535923A (ja) * 2018-09-12 2021-12-23 ザビエル・ユニバーシティ・オブ・ルイジアナXavier University Of Louisiana エストロゲン受容体を標的にするアンタゴニスト
US11850246B2 (en) 2020-08-04 2023-12-26 Novmetapharma Co., Ltd. Method for treatment of cytokine release syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
EP0260066B1 (de) * 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifenderivate

Also Published As

Publication number Publication date
AU664161B2 (en) 1995-11-09
JPH06504522A (ja) 1994-05-26
EP0551434A1 (de) 1993-07-21
DE69114719T2 (de) 1996-10-10
EP0551434B1 (de) 1995-11-15
WO1992006068A1 (en) 1992-04-16
DE69114719D1 (de) 1995-12-21
AU8868291A (en) 1992-04-28
CA2092996A1 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
ATE130293T1 (de) Tamoxifenderivate mit hoher affinität und ihre verwendung.
Zhuang et al. Synthesis And Evaluation of 4-(2'-Methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido] ethyl] piperazine (p-MPPI): A New Iodinated 5-HT1A Ligand
DK0615448T3 (da) Kønssteroidaktivitetsinhibitorer
DK0393838T3 (da) Dopaminreceptorligander og imagografimidler
ATE175198T1 (de) N-acylierte trizyklische azaheteroringe verwendbar als vasopressin-antagonisten
SG65388G (en) Substituted imidazole derivatives and their preparation and use
BR0014808A (pt) Processos de preparação de um composto, e, compostos nitroaromáticos
RU92004509A (ru) Замещенные фенилфенольные соединения, фармацевтическая композиция, способ получения
IL83804A (en) Imidazolylguanidine derivatives, processes for preparing them and pharmaceutical compositions containing them
ATE48835T1 (de) Chinolylglycinamidderivate, verfahren zu ihrer herstellung und therapeutische verwendung als psychotrope.
ES8704917A1 (es) Procedimiento para prepararar derivados de 1-piperazinacarboximida.
CA1252106C (de)
PT73280A (de) Neue imidazol-derivate verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praparate
PT1226122E (pt) Agonistas biciclicos da vasopressina
SE7902866L (sv) 3-0-(beta-d-glukuronopyranosyl)-sojasapogenol b
ATE2423T1 (de) 1-acyloxyphenyl-1,2-diphenylalken-derivate, verfahren zu deren herstellung und eine diese derivate enthaltende pharmazeutische zusammensetzung.
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
ES8500925A1 (es) "procedimiento para la preparacion de n-(2-(((5-(dimetilamino)-metil-2-furanil) metil) tio) etil) -n'- metil-2-nitro 1,1-etenodiamina"
Rybin et al. The inhibiting effect of pertussis toxin on the exchange of guanyl nucleotides bound to transducin from bovine retinal rod outer segment.
ATE79872T1 (de) Aromatasehemmende 4(5)-imidazole.
JPS56158743A (en) Novel aminoalkyl ether derivative
ES1002860U (es) Soporte fortalecedor de senos
RU92016532A (ru) Бензохиназолиновые соединения, способ их получения, фармацевтическая композиция и способ лечения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties